Ravandi, F., Ritchie, E. K., Sayar, H., Strickland, S. A., Craig, M., Selleslag, D. L. D., … Feldman, E. J. (2012). VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Ravandi, Farhad, Ellen K. Ritchie, Hamid Sayar, Stephen Anthony Strickland, Michael Craig, Dominik L. D. Selleslag, Johan Maertens, et al. “VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Ravandi F, Ritchie EK, Sayar H, Strickland SA, Craig M, Selleslag DLD, et al. VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.

Ravandi, Farhad, et al. “VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.

Ravandi F, Ritchie EK, Sayar H, Strickland SA, Craig M, Selleslag DLD, Maertens J, Havelange V, Lancet JE, Ketchum SB, Acton G, Mehta CR, Silva E, Craig A, Fox JA, Stuart RK, Erba HP, Vey N, Schiller GJ, Feldman EJ. VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.